Tadalafil Tablet
Product Images NDC 68071-3781

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3781 2)

Label for Tadalafil 20 mg tablets by NuCare Pharmaceuticals, Inc. The package contains 12 tablets. Each almond-shaped yellow tablet is debossed with '051'. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. in China. The label includes storage instructions and warnings, batch and expiration placeholders, and a QR code.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

Chemical structure diagram of tadalafil, the active ingredient in the product labeled TADALAFIL 20 mg oral tablets by NuCare Pharmaceuticals, Inc. The structure shows the molecular framework including fused rings and substituent groups characteristic of tadalafil.*

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

A set of four line graphs showing differences in blood pressure measurements (systolic and diastolic, standing and supine) over time in hours. Each graph compares tadalafil to placebo, displaying variation with error bars across a 96-hour period.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

Two line graphs showing the effect of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure. The top graph plots standing systolic blood pressure changes, and the bottom graph shows supine systolic blood pressure changes over a 24-hour period after dosing.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

A line graph depicting systolic blood pressure (mmHg) over 12 hours following administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin, with data points at 08:00 and 20:00. Four trend lines compare blood pressure changes for tadalafil and placebo at two daily time points.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 days. The graph includes error bars, with concentration on the y-axis and time on the x-axis spanning 0 to 120 hours.*

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment period for tadalafil 5 mg tablets versus placebo. The y-axis shows change from baseline in IPSS total score, and the x-axis indicates duration of treatment in weeks. The graph demonstrates a greater reduction in IPSS scores with tadalafil compared to placebo, with statistically significant difference indicated at 12 weeks (p<0.01).*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

A line graph comparing change from baseline in IPSS total score over 12 weeks between Tadalafil tablets 5 mg and placebo. The graph shows greater score reduction with Tadalafil from week 1 through week 12, with a significant difference noted at week 4 (p<0.01). The x-axis represents treatment duration in weeks, and the y-axis shows change in score.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

Line chart showing least squares mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows change from baseline values. Symbols indicate statistical significance at various points.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between tadalafil 5 mg tablets and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows score changes. Tadalafil shows a greater reduction in score over time compared to placebo, with a statistically significant difference noted at 12 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.